About City of Hope

City of Hope is an independent biomedical research and treatment organization for cancer, diabetes, and other life-threatening diseases.

Founded in 1913, City of Hope is a leader in bone marrow transplantation and immunotherapy such as CAR T cell therapy. City of Hope’s translational research and personalized treatment protocols advance care throughout the world. Human synthetic insulin, monoclonal antibodies and numerous breakthrough cancer drugs are based on technology developed at the institution. AccessHope™, a subsidiary launched in 2019 serves employers and their health care partners by providing access to City of Hope’s specialized cancer expertise.

A National Cancer Institute-designated comprehensive cancer center and a founding member of the National Comprehensive Cancer Network, City of Hope is ranked among the nation’s “Best Hospitals” in cancer by U.S. News & World Report and received Magnet Recognition from the American Nurses Credentialing Center. Its main campus is located near Los Angeles, with additional locations throughout Southern California and in Arizona.

City of Hope’s commitment to Diversity, Equity, and Inclusion

We believe diversity, equity and inclusion is key in serving our mission to provide compassionate patient care, drive innovative discovery, and advance vital education focused on eliminating cancer and diabetes in all our communities. Our commitment to Diversity, Equity and Inclusion ensures we bring the full range of skills, perspectives, cultural backgrounds, and experiences to our work -- and that our teams align with the people we serve to build trust and understanding. We are dedicated to fostering a community that embraces diversity - in ideas, backgrounds, and perspectives; this is reflected in our work and represented in our people.

Position Summary

Our group is interested in discovering novel genetic and epigenetic regulations and deciphering their underlying molecular mechanisms in normal developmental processes (e.g., hematopoiesis) and tumorigenesis (e.g., leukemogenesis). We cover research areas with relevance to Hematology, Immunology, and Cancer Biology, with an emphasis on RNA epigenetics (mainly focusing on the N⁶ methyladenosine (m⁶A) modification) and DNA epigenetics (mainly focusing on the TET1/2/3-mediated DNA demethylation) associated basic and translational research. Our research involves experiments with primary human cancer cells, cancer and stem cell transplantation models, mouse genetics, classic molecular, biochemistry and cell biology, functional genomics, signal transduction, and large-scale data analysis and computational biology.

Methods/Techniques used in the Lab:
Including but not limited to: Flow cytometry, mass spectrometry/quantitative phospho-profiling, CyTOF, mouse genetics, bone marrow transplantation assays, retroviral gene delivery, whole exome sequencing and RNA-seq-analysis of clonal evolution of cancer, m⁶A/5hmC dot blots, m⁶A-seq, 5hmC-seq, ChIP-seq, RIP-seq, PAR-CLIP-seq, pre-clinical drug testing in xenotransplantation models.

Basic education, experience and skills required for consideration:

• A Ph.D. degree in life or biomedical sciences, or a related discipline is required.
• Solid background in biochemistry, mouse model studies, hematology, epigenetics, immunology, pathology, and/or stem cell research is preferred
• The candidates should not have more than three years of postdoc training experience.
• The candidates should be highly motivated individuals with the ability to work in a team environment and with good oral and written communication skills in English.

Additional Information:

As a condition of employment, City of Hope requires staff to comply with all state and federal vaccination mandates.

• For more information on Dr. Jianjun Chen’s research please visit,here.
• Your application, including CV, brief motivation statement, and contact information of three scientific mentors (references), should be saved as a single PDF.